SCHEMBL16331975

SCHEMBL16331975

Cn1cc(-c2cc3cnc(Nc4cccc(NS(C)(=O)=O)c4)cc3n2Cc2ccccc2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 3/20 0.54
▸ TTK P33981 2/20 0.43
▸ DHX9 Q08211 1/20 0.42
▸ WNT1 P04628 3/20 0.41
▸ GSK3B P49841 3/20 0.41
▸ DYRK1A Q13627 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ MET P08581 4/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16331434 0.87 FYN (0.53) FYNTTKWNT1GSK3BDYRK1A
SCHEMBL12492274 0.87 FYN (0.56) FYNTTKWNT1GSK3BDYRK1A
SCHEMBL12492967 0.86 FYN (0.60) FYNTTKWNT1GSK3BDYRK1A
SCHEMBL17555243 0.85 FYN (0.55) FYNTTKWNT1GSK3BDYRK1A
SCHEMBL12492817 0.82 FYN (0.57) FYNTTKWNT1GSK3BDYRK1A
SCHEMBL12492914 0.81 FYN (0.61) FYNTTKFGFR1SRC
SCHEMBL12492484 0.81 FYN (0.59) FYNTTKWNT1GSK3BDYRK1A
SCHEMBL12492438 0.80 FYN (0.55) FYNTTKWNT1GSK3BDYRK1A
SCHEMBL12493054 0.75 TTK (0.59) FYNTTK
SCHEMBL12492656 0.75 PRKDC (0.57) FYNTTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US claimed
WO-2014207260-A1 PYRROLO[3,2-C]PYRIDINE COMPOUNDS AS G-PROTEIN-COUPLED RECEPTOR KINASE 5 (GRK5) MODULATORS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — WO claimed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP claimed
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US disclosed
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-03-19 — — US disclosed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY GCKR, GRK4, GRK5 FYN 574/4885TTK 191/4885DHX9 3655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback